Abstract
In previous year the long-awaited results of three clinical trials investigating long-term therapy with acetylsalicylic acid in primary prevention were published. These studies enrolled various groups of patients with elevated cardiovacular risk.
Although there was a mild decrease in the incidence of cardiovascular ischaemic events, the net clinical benefit of acetylsalicylic acid therapy was not established because it caused increased risk of bleeding complications.